1. Generics Bulletin
  2. >>Products
  3. >>Generics

FDA Hands Lannett Goal Date On Generic Advair

Lannett: Anticipate More Than One Review Cycle

 
• By Dean Rudge

Lannett continues to eye the potential launch of its partnered Advair generic next year, after the lucrative respiratory asset was accepted for filing by the FDA.

Human_Respiratory_System
Lannett has two significant respiratory assets • Source: Shutterstock

The US Food and Drug Administration has accepted for filing Lannett’s application for a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol), although the US-based firm continues to anticipate “more than one FDA review cycle of this opportunity given the inherent complexity associated with a drug/device combination inhalation product.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 
• By Urtė Fultinavičiūtė

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.